About: COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED‐ZONE declaration

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED‐ZONE declaration Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED‐ZONE declaration
Creator	Bragazzi, Nicola Damiani, Giovanni Khalaf Kridin, \| Malagoli, Piergiorgio Pacifico, Alessia Pigatto, Paolo Riccò, Matteo
Source	Medline; PMC
abstract	SARS‐CoV‐2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. We aimed to assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID‐19. We performed a cross‐sectional, questionnaire‐based survey on 98/105 consecutive dermatological patients treated with biologics—51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID‐19 related to (a) epidemiology, (b) pathogenesis, (c) clinical symptoms, (d) preventive measures, and (e) attitudes. Patients data and questionnaires were collected. Despite only 8.1% thought that biologics may increase the risk of COVID‐19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients (P = .001) with higher scholarity level (P = .005) displayed higher knowledge of COVID‐19. Patients with lower DLQI (P = .006), longer disease duration (P = .051) and lower scholarity (P = .007) have thought to discontinue/modify autonomously their biologic therapy. At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation vs discontinuation and modification vs no modification, respectively. Dermatologists should promote COVID‐19 knowledge to prevent biologics disruption.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1111/dth.13508
bibo:pmid	32415727
has license	no-cc
sha1sum (hex)	82bb0e1235ebbe936da94d7754232902e144f678
schema:url	https://doi.org/10.1111/dth.13508
resource representing a document's title	COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED‐ZONE declaration
has PubMed Central identifier	PMC7267153
has PubMed identifier	32415727
schema:publication	Dermatol Ther
resource representing a document's body	covid:82bb0e1235ebbe936da94d7754232902e144f678#body_text
is schema:about of	named entity 'SUFFERING' named entity 'BIOLOGICS' named entity 'DOSAGE' named entity 'COVID-19' named entity 'PLAQUE PSORIASIS' named entity 'PREVENTIVE' named entity 'PATIENTS' named entity 'Dermatologists' named entity 'pandemics' named entity 'health literacy' named entity 'SARS-CoV-2' named entity 'atopic dermatitis' named entity 'plaque psoriasis' named entity 'biologic therapy' named entity 'biologics' named entity 'hidradenitis suppurativa' named entity 'RED-ZONE' named entity 'Italian' named entity 'dermatological' named entity 'atopic dermatitis' named entity 'dermatological' named entity 'pathogenetic' named entity 'COVID-19' named entity 'skewness' named entity 'Eczema Area and Severity Index' named entity 'desquamation' named entity 'COPD' named entity 'dermatological' named entity 'comorbidities' named entity 'biologic therapy' named entity 'COVID-19' named entity 'biological therapy' named entity 'pandemics' named entity 'PASI' named entity 'personal protective equipment (PPE' named entity 'hand eczema' named entity 'Helsinki Declaration' named entity 'comorbidities' named entity 'regression analysis' named entity 'infection' named entity 'epidemiology' named entity 'pathogenesis' named entity 'tropism' named entity 'personal protective equipment (PPE' named entity 'biologic therapies' named entity 'dermatological' named entity 'N95 masks' named entity 'inflammation' named entity 'dermatological' named entity 'preventive measures' named entity 'dermatologists' named entity 'COVID-19' named entity 'medical history' named entity 'COVID-19' named entity 'higher risk' named entity 'psoriatic arthritis' named entity 'dermatologists' named entity 'Psoriatic' named entity 'atopic dermatitis' named entity 'PSoriatic Arthritis' named entity 'biologics' named entity 'Autoinflammatory Disease' named entity 'biologics' named entity 'respiratory airways' named entity 'dermatologists' named entity 'sample size' named entity 'COVID-19' named entity '21.4%' named entity 'kurtosis' named entity 'hidradenitis suppurativa' named entity 'Quality of Life' named entity 'goggles' named entity 'skin disorders' named entity 'PASI' named entity 'SARS-CoV2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software